Fosun Pharmaceutical (600196.SH) holding subsidiary signs cooperation and option agreement with Clavis Bio

Zhitong Finance App News, Fosun Pharmaceutical (600196.SH) announced that on December 18, 2025, the company's holding subsidiary Fosun Pharmaceutical Industry and partner Clavis Bio signed a “Cooperation and Choice Agreement”. According to the agreement, within the agreed cooperation period, Fosun Pharmaceutical Industry and ClavisBio will jointly select targets (based on Clavis Bio nominations) and promote pre-clinical development of selected target compounds (i.e. cooperative projects). Clavis Bio has the right to choose an exclusive license for development, production and commercialization of such cooperative projects on a global scale other than within China, Hong Kong and Macau; regardless of whether the partner exercises these options, the Group enjoys the exclusive right to develop, manufacture and commercialize such cooperative projects within China, Hong Kong and Macau.

If a cooperative project in this cooperation is selected by Clavis Bio, the Group will be able to receive up to $362.5 million in payments (including non-refundable administration fees, development registration milestone payments and sales milestone payments), and can charge an agreed percentage of royalties based on the net sales of the products involved in the cooperation project within the licensing area; in addition, the Group will also obtain Clavis Bio's controlling shareholder (i.e. Aditum Bio Fund) at zero consideration 3) Minority shares of the agreed proportion of the new project company established separately for this cooperative project.

The purpose of this cooperation is to give full play to the R&D advantages of the two partners, further enrich the Group's high-value product pipeline reserves, accelerate the global clinical development and commercialization process of this (etc.) pipeline through potential external licensing, and continue to expand the overseas layout of the Group's innovative products.